Docusign Inc vs Sanofi SA — how do they compare? Docusign Inc trades at $58.51 (market cap $11.33B), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 9.2× Docusign Inc's market cap, and Sanofi SA pays a 5.55% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| DOCU | SNY | |
|---|---|---|
Market Cap | $11.33B | $104.30B |
Sector | Technology | Health |
52-Week High | $85.01 | $52.34 |
52-Week Low | $41.75 | $41.33 |
Enterprise Value | $10.70B | $124.19B |
Dividend Yield | — | 5.55% |
Trailing returns across standard periods
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →